Isomerization of a Single Aspartyl Residue of Anti-Epidermal Growth Factor Receptor Immunoglobulin γ2 Antibody Highlights the Role Avidity Plays in Antibody Activity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
A new isoform of the light chain of a fully human monoclonal immunoglobulin gamma2 (IgG2) antibody panitumumab against human epidermal growth factor receptor (EGFR) was generated by in vitro aging. The isoform was attributed to the isomerization of aspartate 92 located between phenylalanine 91 and histidine 93 residues in the antigen-binding region. The isomerization rate increased with increased temperature and decreased pH. A size-exclusion chromatography binding assay was used to show that one antibody molecule was able to bind two soluble extracellular EGFR molecules in solution, and isomerization of one or both Asp-92 residues deactivated one or both antigen-binding regions, respectively. In addition, isomerization of Asp-92 showed a decrease in in vitro potency as measured by a cell proliferation assay with a 32D cell line that expressed the full-length human EGFR. The data indicate that antibodies containing either one or two isomerized residues were not effective in inhibiting EGFR-mediated cell proliferation, and that two unmodified antigen binding regions were needed to achieve full efficacy. For comparison, the potency of an intact IgG1 antibody cetuximab against the same receptor was correlated with the bioactivity of its individual antigen-binding fragments. The intact IgG1 antibody with two antigen-binding fragments was also much more active in suppressing cell proliferation than the individual fragments, similar to the IgG2 results. These results indicated that avidity played a key role in the inhibition of cell proliferation by these antibodies against the human EGFR, suggesting that their mechanisms of action are similar.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, if a basic species arises due to isomerization or succinimide, there may be inactivation of the molecule or an illicit immune response. 32”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [32]
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Biophysical Chemistry: Part II: Techniques for the Study of Biological Structure and Function
Cantor, C. R., & SCHIMMEL, P. R. (1980) · Cited by 861
On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.
Parham, P. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.6.2895 · Cited by 413
Trafficking of the ErbB receptors and its influence on signaling
Wiley, H. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00002-8 · Cited by 348
CLARKE, S. (1987) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1987.tb03390.x · Cited by 338
Cleland, J. L., Lam, X., Kendrick, B., Yang, J., Yang, T., Overcashier, D., Brooks, D., Hsu, C., & Carpenter, J. F. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200103)90:3<310::aid-jps6>3.0.co;2-r · Cited by 299
Isoaspartate in peptides and proteins: formation, significance, and analysis
Aswad, D. W., Paranandi, M. V., & Schurter, B. T. (2000) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(99)00230-7 · Cited by 266
Dillon, T. M., Bondarenko, P. V., Rehder, D. S., Pipes, G. D., Kleemann, G. R., & Ricci, M. S. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.01.016 · Cited by 189
Self-citationGabrielson, J. P., Brader, M. L., Pekar, A. H., Mathis, K. B., Winter, G., Carpenter, J. F., & Randolph, T. W. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20760 · Cited by 175
Oliyai, C., & Borchardt, R. T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018981231468 · Cited by 148
Research works printed but not linked: 46
- Carpenter G., 2000, Bioassays 22, 697−707.
- Wu D. G., 1990, Proc. Natl. Acad. Sci. U.S.A. 87
- Burgess A. W., 2003, Mol. Cell 12, 541−552.
- Franklin M. C., 2004, Cancer Cell 5, 317−328.
- Dawson J. P., 2005, Mol. Cell. Biol. 25, 7734−7742.
- Hynes N. E., 2005, Nat. Rev. Cancer, 5
- Herbst R. S., 2002, Cancer 94, 1593−1611.
- Kawamoto T., 1983, Proc. Natl. Acad. Sci. U.S.A. 80
- Foon K. A., 2004, Int. J. Radiat. Oncol. Biol. Phys., 58
- Scott A. M., 2007, Proc. Natl. Acad. Sci. U.S.A. 104
- Adams G. P., 2006, Clin. Cancer Res. 12, 1599−1605.
- Gan H. K., 2007, J. Biol. Chem., 282
- Geiger T., 1987, J. Biol. Chem., 262
- Oliyai C., 1994, Pharm. Res. 11, 751−758.
- Johnson B. A., 1989, J. Biol. Chem., 264
- Potter S. M., 1993, III, and IV, Protein Sci. 2, 1648−1663.
- Lam X. M., 1997, J. Pharm. Sci., 86
- Stephenson R. C., 1989, J. Biol. Chem., 264
- Xiao G., 2007, Anal. Chem. 79, 2714−2721.
- Cacia J., 1996, Biochemistry 35
- Harris R. J., 2001, J. Chromatogr. B: Biomed. Sci. Appl. 752, 233−245.
- Wakankar A. A., 2007, J. Pept. Sci., 96
- Wakankar A. A., 2007, Biochemistry 46, 1534−1544.
- Di Donato A., 1993, J. Biol. Chem., 268
- Zhang W., 2002, Pharm. Res. 19, 1223−1231.
- Chelius D., 2005, Anal. Chem. 77, 6004−6011.
- Qian R. L., 1997, J. Chromatogr. A, 787
- Santora L. C., 2001, Anal. Biochem. 299, 119−129.
- Yang X. D., 1999, Cancer Res. 59, 1236−1243.
- Jakobovits A., 2007, Nat. Biotechnol. 25, 1134−1143.
- Goldstein N. I., 1995, Clin. Cancer Res. 1, 1311−1318.
- Li S., 2005, Cancer Cell 7, 301−311.
- Harding J., 2005, Drugs Today 41, 107−127.
- Zhang Z., 2004, Anal. Chem. 76, 3908−3922.
- Gadgil H. S., 2006, Anal. Biochem. 355, 165−174.
- Korman A. J., 1987, Proc. Natl. Acad. Sci. U.S.A. 84
- Ritz-Timme S., 2002, Ageing Res. Rev., 1, 59
- Chu G. C., 2007, J. Pharm. Res., 24
- Pierce J. H., 1988, Science 239, 628−631.
- Yang S., 2006, Cancer Res. 66, 6990−6997.
- Chen Y. R., 2006, Oncogene 25, 1205−1215.
- Fan Z., 1993, Cancer Res. 53, 4322−4328.
- Fan Z., 1994, J. Biol. Chem., 269
- Honegger A., 2001, J. Mol. Biol., 309
- Friedman L. M., 2005, Proc. Natl. Acad. Sci. U.S.A. 102
- Foltz, I. N., King, C. T., and Liang, M. (2007) Panitumumab induces internalization of the epidermal growth factor receptor [abstract B43 plus poster], 17th American Association for Cancer Research−National Cancer Institute−European Organization for the Research and Treatment of Cancer (AACR-NCI Disclosure EORTC) International Conference on Molecular Targets and Cancer Therapeutics; Nov 14−18, 2005, Philadelphia, PA; p 136.
Cited by
Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,098
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Mass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 316
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
In vitro and in vivo modifications of recombinant and human IgG antibodies
Liu, H., Ponniah, G., Zhang, H.-M., Nowak, C., Neill, A., Gonzalez-Lopez, N., Patel, R., Cheng, G., Kita, A. Z., & Andrien, B. (2014) · mAbs · doi:10.4161/mabs.29883 · Cited by 168
Garrido, G., Tikhomirov, I. A., Rabasa, A., Yang, E. C. C., Gracia, E., Iznaga, N., Fernandez, L. E., Crombet, T., Kerbel, R. S., & Pérez, R. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.4.14097 · Cited by 165
Haberger, M., Bomans, K., Diepold, K., Hook, M., Gassner, J., Schlothauer, T., Zwick, A., Spick, C., Kepert, J. F., Hienz, B., et al. (2014) · mAbs · doi:10.4161/mabs.27876 · Cited by 162
Sydow, J. F., Lipsmeier, F., Larraillet, V., Hilger, M., Mautz, B., Mølhøj, M., Kuentzer, J., Klostermann, S., Schoch, J., Voelger, H. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100736 · Cited by 161
Deamidation and isomerization liability analysis of 131 clinical-stage antibodies
Lu, X., Nobrega, R. P., Lynaugh, H., Jain, T., Barlow, K., Boland, T., Sivasubramanian, A., Vásquez, M., & Xu, Y. (2019) · mAbs · doi:10.1080/19420862.2018.1548233 · Cited by 141
Structural and functional characterization of the trifunctional antibody catumaxomab
Chelius, D., Ruf, P., Gruber, P., Plöscher, M., Liedtke, R., Gansberger, E., Heß, J., Wasiliu, M., & Lindhofer, H. (2010) · mAbs · doi:10.4161/mabs.2.3.11791 · Cited by 152
Self-citationMacro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies
Beck, A., & Liu, H. (2019) · Antibodies · doi:10.3390/antib8010018 · Cited by 138
Characterization of antibody aggregation: Role of buried, unpaired cysteines in particle formation
Brych, S. R., Gokarn, Y. R., Hultgen, H., Stevenson, R., Rajan, R. S., & Matsumura, M. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21868 · Cited by 126
Self-citationAnalytical comparability study of recombinant monoclonal antibody therapeutics
Ambrogelly, A., Gozo, S., Katiyar, A., Dellatore, S. M., Kune, Y., Bhat, R., Sun, J., Li, N., Wang, D., Nowak, C., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1438797 · Cited by 106
Wang, Y., Li, X., Liu, Y.-H., Richardson, D., Li, H., Shameem, M., & Yang, X. (2016) · mAbs · doi:10.1080/19420862.2016.1226715 · Cited by 95
Alvarez, M., Tremintin, G., Wang, J. P., Eng, M., Kao, Y., Jeong, J., Ling, V. T., & Borisov, O. V. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.07.033 · Cited by 101
Li, Y., Polozova, A., Gruia, F., & Feng, J. (2014) · Analytical Chemistry · doi:10.1021/ac404218t · Cited by 93
Schmid, I., Bonnington, L. S., Gerl, M., Bomans, K., Thaller, A., Wagner, K., Schlothauer, T., Falkenstein, R., Zimmermann, B., Kopitz, J., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0032-8 · Cited by 94
Yan, Y., Wei, H., Fu, Y., Jusuf, S., Zeng, M., Ludwig, R. T., Krystek, S. R., Chen, G., Tao, L., & Das, T. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02800 · Cited by 92
Valliere‐Douglass, J. F., Wallace, A. M. R., & Balland, A. (2008) · Journal of Chromatography A · doi:10.1016/j.chroma.2008.10.078 · Cited by 89
Atmanène, C., Wagner‐Rousset, E., Malissard, M., Chol, B., Robert, A., Corvaïa, N., DORSSELAER, A. V., Beck, A., & Cianférani, S. (2009) · Analytical Chemistry · doi:10.1021/ac9007557 · Cited by 88
Lambeth, T. R., Riggs, D. L., Talbert, L. E., Tang, J. Y., Coburn, E., Kang, A. S., Noll, J. M., Augello, C. J., Ford, B. D., & Julian, R. R. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00369 · Cited by 88
Rigid nanoparticle-based delivery of anti-cancer siRNA: Challenges and opportunities
Wang, Z., Liu, G., Zheng, H., & Chen, X. S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.020 · Cited by 87
Terral, G., Beck, A., & Cianférani, S. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.03.044 · Cited by 76
Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles
Chung, S., Tian, J., Tan, Z., Chen, J., Lee, J., Borys, M., & Li, Z. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26587 · Cited by 72
Liu, M., Cheetham, J., Cauchon, N. S., Ostovic, J., Ni, W., Ren, D., & Zhou, Z. S. (2011) · Analytical Chemistry · doi:10.1021/ac202652z · Cited by 65
Gandhi, S. P., Ren, D., Xiao, G., Bondarenko, P. V., Sloey, C. J., Speed, M. A., & Krishnan, S. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0536-0 · Cited by 63
Self-citationWang, T., Kumru, O. S., Li, Y., Wang, Y. J., Zhang, J., Kim, J. H., Joshi, S. B., Middaugh, C. R., & Volkin, D. B. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23645 · Cited by 61
Du, Y., Wang, F., May, K., Xu, W., & Liu, H. (2012) · Analytical Chemistry · doi:10.1021/ac3013362 · Cited by 51
Structural Elucidation of Post-Translational Modifications in Monoclonal Antibodies
Li, W., Kerwin, J. L., Schiel, J. E., Formolo, T., Davis, D., Mahan, A. D., & Benchaar, S. A. (2015) · ACS symposium series · doi:10.1021/bk-2015-1201.ch003 · Cited by 57
Analysis of Glutamine Deamidation: Products, Pathways, and Kinetics
Riggs, D. L., Silzel, J. W., Lyon, Y. A., Kang, A. S., & Julian, R. R. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03127 · Cited by 57
Shi, L., Xiao, G., Dillon, T. M., Ricci, M. S., & Bondarenko, P. V. (2020) · mAbs · doi:10.1080/19420862.2020.1739825 · Cited by 56
Self-citationZhang, J., Yip, H. L., & Katta, V. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.11.040 · Cited by 55
Geist, B. J., Clements‐Egan, A., Yang, T., Dong, Y., & Shankar, G. (2013) · Bioanalysis · doi:10.4155/bio.12.304 · Cited by 53
Sequence and Solution Effects on the Prevalence of d -Isomers Produced by Deamidation
Riggs, D. L., Gomez, S. V., & Julian, R. R. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00686 · Cited by 52
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
Beck, A., Nowak, C., Meshulam, D., Reynolds, K., Chen, D. J., Pacardo, D. B., Nicholls, S. B., Carven, G. J., Gu, Z., Fang, J., et al. (2022) · Antibodies · doi:10.3390/antib11040073 · Cited by 51
Stability of Protein Pharmaceuticals: Recent Advances
Manning, M. C., Holcomb, R. E., Payne, R. W., Stillahn, J. M., Connolly, B. D., Katayama, D. S., Liu, H., Matsuura, J. E., Murphy, B. M., Henry, C. S., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03726-x · Cited by 48
Jing, S., Gou, J.-X., Gao, D., Wang, H., Yao, S., & Lin, D. (2019) · Separation and Purification Technology · doi:10.1016/j.seppur.2019.116136 · Cited by 48
Mozziconacci, O., Kerwin, B. A., & Schöneich, C. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100193b · Cited by 46
Structural and functional consequences of age-related isomerization in α-crystallins
Lyon, Y. A., Collier, M., Riggs, D. L., Degiacomi, M. T., Benesch, J. L. P., & Julian, R. R. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.007052 · Cited by 44
Ion mobility in the pharmaceutical industry: an established biophysical technique or still niche?
Campuzano, I. D., & Lippens, J. L. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.11.008 · Cited by 42
Identification of Sequence Similarities among Isomerization Hotspots in Crystallin Proteins
Lyon, Y. A., Sabbah, G. M., & Julian, R. R. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00073 · Cited by 41
Assessing analytical methods to monitor isoAsp formation in monoclonal antibodies
Eakin, C. M., Miller, A. K., Kerr, J., Kung, J., & Wallace, A. M. R. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00087 · Cited by 38
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue
Irudayanathan, F. J., Zarzar, J., Lin, J., & Izadi, S. (2022) · mAbs · doi:10.1080/19420862.2022.2143006 · Cited by 37
Yang, H., Lyutvinskiy, Y., Soininen, H. S., & Zubarev, R. A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110626 · Cited by 37
Pollastrini, J., Dillon, T. M., Bondarenko, P. V., & Chou, R. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.03.001 · Cited by 37
Self-citationUse of In Vitro Systems To Model In Vivo Degradation of Therapeutic Monoclonal Antibodies
Yang, N., Tang, Q., Hu, P., & Lewis, M. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00183 · Cited by 36
Hambly, D. M., Banks, D. D., Scavezze, J. L., Siska, C. C., & Gadgil, H. S. (2009) · Analytical Chemistry · doi:10.1021/ac901258g · Cited by 32
Differentiating N-Terminal Aspartic and Isoaspartic Acid Residues in Peptides
Sargaeva, N. P., Lin, C., & O’Connor, P. B. (2011) · Analytical Chemistry · doi:10.1021/ac201223d · Cited by 32
Haberger, M., Heidenreich, A.-K., Hook, M., Fichtl, J., Lang, R., Cymer, F., Adibzadeh, M., Kuhne, F., Wegele, H., Reusch, D., et al. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00446 · Cited by 31
Isomerization of Asp–Asp Motif in Model Peptides and a Monoclonal Antibody Fab Fragment
Yi, L., Adeniji, N., Gikanga, B., Zhang, J., Wang, Y. J., Chih, H., & Sharma, V. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23423 · Cited by 27
Dick, L. W., Qiu, D., & Cheng, K. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.09.031 · Cited by 24
Cohen, J. R., Brych, S. R., Prabhu, S., Bi, V., Elbaradei, A., Tokuda, J. M., Xiang, C. D., Hokom, M. M., Cui, X., Ly, C. G., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03678-2 · Cited by 23
Dick, L. W., Qiu, D., Wong, R. B., & Cheng, K. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22561 · Cited by 23
Hinterholzer, A., Stanojlović, V., Regl, C., Huber, C. G., Cabrele, C., & Schubert, M. (2021) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00356-4 · Cited by 23
Arthur, K. K., Gabrielson, J. P., Hawkins, N., Anafi, D., Wypych, J., Nagi, A., Sullivan, J. K., & Bondarenko, P. V. (2012) · Biochemistry · doi:10.1021/bi2007806 · Cited by 23
Self-citationAnalytical tools for the characterization of deamidation in monoclonal antibodies
Spanov, B., Govorukhina, N. I., van de Merbel, N. C., & Bischoff, R. (2021) · Journal of Chromatography Open · doi:10.1016/j.jcoa.2021.100025 · Cited by 22
Apostoł, I., Bondarenko, P. V., Ren, D., Semin, D. J., Wu, C., Zhang, Z., & Goudar, C. T. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.08.001 · Cited by 22
Self-citationMeltretter, J., Wüst, J., Dittrich, D., Lach, J., Ludwig, J., Eichler, J., & Pischetsrieder, M. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00630 · Cited by 22
Valliere‐Douglass, J. F., Connell‐Crowley, L., Jensen, R. M., Schnier, P. D., Trilisky, E. I., Leith, M., Follstad, B. D., Kerr, J., Lewis, N. E., Vunnum, S., et al. (2010) · Protein Science · doi:10.1002/pro.495 · Cited by 22
Valliere‐Douglass, J. F., Lewis, P., Salas‐Solano, O., & Jiang, S. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24276 · Cited by 20
Alvarenga, M. L., Kikhney, J., Hannewald, J., Metzger, A. U., Steffens, K. ‐., Bomke, J., Krah, A., & Wegener, A. A. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.10.039 · Cited by 19
Temperature-induced unfolding, aggregation, and interaction of therapeutic monoclonal antibodies
Menzen, T. (2014) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17520 · Cited by 19
Separation Methods and Orthogonal Techniques
Michels, D. A., Ip, A. Y., Dillon, T. M., Brorson, K., Lute, S. C., Chavez, B. K., Prentice, K. M., Brady, L. J., & Miller, K. J. (2015) · ACS symposium series · doi:10.1021/bk-2015-1201.ch005 · Cited by 18
Self-citationPatel, C. N., Bauer, S. P., Davies, J., Durbin, J. D., Shiyanova, T. L., Zhang, K., & Tang, J. X. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/s0022-3549(15)00185-9 · Cited by 18
Jing, S., Shi, C., Leong, H. Y., Yuan, J., Gao, D., Wang, H., Yao, S., & Lin, D. (2021) · Engineering in Life Sciences · doi:10.1002/elsc.202000094 · Cited by 16
Bioprocess Challenges in Purification of Therapeutic Protein Charge Variants
Gupta, T., Kumar, A., & Seshadri, S. (2023) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-023-0078-4 · Cited by 15
Krittanai, S., Putalun, W., Sakamoto, S., Tanaka, H., Juengwatanatrakul, T., & Yusakul, G. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05502-7 · Cited by 15
Shi, L., Xiao, G., Dillon, T. M., McAuley, A., Ricci, M. S., & Bondarenko, P. V. (2021) · mAbs · doi:10.1080/19420862.2021.1887612 · Cited by 14
Self-citationIn-source decay characterization of isoaspartate and β-peptides
Yu, X., Sargaeva, N. P., Thompson, C. J., Costello, C. E., & Lin, C. (2015) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2015.07.013 · Cited by 14
Bondarenko, P. V., Nichols, A. C., Xiao, G., Shi, L., Chan, P. K., Dillon, T. M., Garcés, F., Semin, D. J., & Ricci, M. S. (2021) · mAbs · doi:10.1080/19420862.2021.1887629 · Cited by 13
Self-citationBashyal, A., Hui, J. O., Flick, T. G., Dykstra, A. B., Zhang, Q., Campuzano, I. D. G., & Brodbelt, J. S. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02025 · Cited by 13
Игоревич, П. С., Indeykina, M. I., Popov, I. A., Kononikhin, A. S., Bocharov, K. V., Kozin, S. A., Makarov, A. А., & Николаев, Е. Н. (2017) · European Journal of Mass Spectrometry · doi:10.1177/1469066717730544 · Cited by 13
Modifications of recombinant monoclonal antibodies in vivo
Liu, H., Nowak, C., & Patel, R. (2019) · Biologicals · doi:10.1016/j.biologicals.2019.03.006 · Cited by 13
Zhao, J., Peng, W., Dong, X., & Mechref, Y. S. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00659 · Cited by 13
Hui, J. O., Flick, T. G., Loo, J. A., & Campuzano, I. D. G. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00370 · Cited by 13
Design and optimization of membrane chromatography for monoclonal antibody charge variant separation
Nadar, S., Somasundaram, B., Charry, M., Billakanti, J. M., Shave, E., Baker, K. N., & Lua, L. H. L. (2022) · Biotechnology Progress · doi:10.1002/btpr.3288 · Cited by 12
Readel, E. R., Patel, A. M., Putman, J. I., Du, S., & Armstrong, D. W. (2023) · Scientific Reports · doi:10.1038/s41598-023-38788-1 · Cited by 12
Noncovalent Mass Spectrometry for the Characterization of Antibody/Antigen Complexes
Atmanène, C., Wagner‐Rousset, E., Corvaïa, N., DORSSELAER, A. V., Beck, A., & Cianférani, S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-327-5_16 · Cited by 11
Bickel, F., Griaud, F., Kern, W., Kröner, F., Gritsch, M., Dayer, J., Barteau, S., Denefeld, B., Kao‐Scharf, C., Lang, M., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2151075 · Cited by 10
Self-citationHuman Fc receptor-like 5 distinguishes IgG2 disulfide isoforms and deamidated charge variants
Alabi, O., Dement-Brown, J., & Tolnay, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.10.020 · Cited by 10
Chapter 1: Monoclonal Antibodies: Structure, Physicochemical Stability, and Protein Engineering
Mills, B. J., Moussa, E. M., & Jameel, F. (2020) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-31415-6_1 · Cited by 9
Ramachander, R., & Rathore, N. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-7978-9_2 · Cited by 8
Kern, W., Mende, R., Denefeld, B., Sackewitz, M., & Chelius, D. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.02.017 · Cited by 8
Self-citationZhou, K., Cao, X., Bautista, J., Chen, Z., Hershey, N. D., Ludwig, R. T., Tao, L., Zeng, M., & Das, T. K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.018 · Cited by 8
Heterogeneity of IgGs: Role of Production, Processing, and Storage on Structure and Function
Barton, C., Spencer, D., Levitskaya, S. V., Feng, J., Harris, R. J., & Schenerman, M. A. (2014) · ACS symposium series · doi:10.1021/bk-2014-1176.ch003 · Cited by 7
Deuterium Labeling of Isoaspartic and Isoglutamic Acids for Mass Spectrometry Analysis
Miyagi, M., Kiesel, E., Neumbo, K., & Nakazawa, T. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05194 · Cited by 6
Woodall, D. W., Thomson, C. A., Dillon, T. M., McAuley, A., Green, L. B., Foltz, I. N., & Bondarenko, P. V. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05554 · Cited by 6
Self-citationLund, A. L., Ren, D., Rogers, R. S., Rouse, J. C., Yu, X. C., & Valliere‐Douglass, J. F. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.11.007 · Cited by 6
Adhikari, J., Heffernan, J. R., Edeling, M. A., Fernández, E., Jethva, P. N., Diamond, M., Fremont, D. H., & Gross, M. L. (2024) · Biomolecules · doi:10.3390/biom14030374 · Cited by 5
Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics
Kim, W., Kang, K. H., & Suh, J.-K. (2018) · InTech eBooks · doi:10.5772/intechopen.79107 · Cited by 5
Chae, H., Cho, S., Jeong, M., Kwon, K., Choi, D., Lee, J., Nam, W., Hong, J., Lee, J., Yoon, S.-J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136696 · Cited by 5
Countercurrent preferential precipitation of acidic variants from monoclonal antibody pools
Rumanek, T., Kołodziej, M., Piątkowski, W., & Antos, D. (2024) · Chemical Engineering Research and Design · doi:10.1016/j.cherd.2024.01.001 · Cited by 4
Mass Spectrometric Characterization in Protein Therapeutics Discovery
Mo, J., Tymiak, A. A., & Chen, G. (2013) · Springer eBooks · doi:10.1007/978-1-4419-7862-2_5 · Cited by 4
Cao, M., Mo, W., Shannon, A. G., Wei, Z., Washabaugh, M. W., & Cash, P. W. (2016) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2015.006239 · Cited by 4
Dynamic pH profiles drive higher cell‐specific and volumetric productivity
Klaubert, S. R., Chitwood, D. G., Peng, D., Redman, E., Anderson, J. Y. L., Sandoval, N. R., & Harcum, S. W. (2026) · Biotechnology Progress · doi:10.1002/btpr.70080 · Cited by 3
Gupta, S., Schöneich, C., & Rathore, A. S. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114295 · Cited by 3
Geist, B. J., Clements‐Egan, A., & Yang, T. (2017) · Wiley eBooks · doi:10.1002/9781119371779.ch10 · Cited by 3
Sandberg, M. W., Bunkenborg, J., Thyssen, S., Villadsen, M., & Kofoed, T. (2021) · Amino Acids · doi:10.1007/s00726-021-03004-9 · Cited by 3
Metadata
- Authors
- Rehder, D. S., Chelius, D., McAuley, A., Dillon, T. M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D. N., Matsumura, M., & Bondarenko, P. V.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Rehder, Douglas S.
- Bondarenko, Pavel V.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-01-31
- Volume
- 47
- Issue
- 8
- Pages
- 2518-2530
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2018172073
- Cited by
- 110
- References
- 24
- Citations by year
- 2025: 1 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 12 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 10 · 2013: 7 · 2012: 4
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- anti-EGFR monoclonal antibody, panitumumab, cetuximab, antibody avidity, antigen-binding region, in vitro aging
- MeSH terms
- Panitumumab, Alkylation, Amino Acid Sequence, Antibodies, Monoclonal, Antibody Affinity, Antibody Formation, Aspartic Acid, Cells, Cultured, Chromatography, High Pressure Liquid, Humans, Immunoglobulin gamma-Chains, Immunoglobulin Light Chains, Isomerism, Models, Molecular, Molecular Sequence Data, Oxidation-Reduction, Protein Processing, Post-Translational, Structure-Activity Relationship, Transferases, Protein Isoforms, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.